Tirzepatide vs Retatrutide: Dual vs Triple Agonist for Weight Loss
Compare tirzepatide (dual GLP-1/GIP) vs retatrutide (triple GLP-1/GIP/glucagon). Which next-gen peptide offers more weight loss potential?
| Dimension | tirzepatide | retatrutide | Notes |
|---|---|---|---|
| Weight Loss Efficacy | 20-26% | 24-26% | Both show similar peak weight loss. Retatrutide Phase 2 data comparable to tirzepatide SURMOUNT results. |
| Mechanism | GLP-1 + GIP | GLP-1 + GIP + Glucagon | Retatrutide adds glucagon receptor activation for enhanced thermogenesis and lipid metabolism. |
| FDA Status | Approved | Phase 3 trials | Tirzepatide FDA-approved. Retatrutide expected to complete Phase 3 trials by 2026-2027. |
| MASH/Liver Benefits | Moderate | Strong signal | Retatrutide showed significant liver fat reduction in trials — glucagon receptor may drive hepatic benefits. |
| Dosing | Weekly | Weekly | Both once-weekly subcutaneous injections. |
| Availability | Prescription | Research only | Tirzepatide widely available. Retatrutide limited to trials and research suppliers. |
Learn more about each peptide
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown greater weight loss than semaglutide in head-to-head trials. It is sold under the brand names Mounjaro (diabetes) and Zepbound (weight management).
Retatrutide
Retatrutide is a triple hormone receptor agonist (GIP/GLP-1/glucagon) currently in Phase 3 clinical trials. Early data shows up to 24% body weight loss, potentially making it the most effective weight loss peptide ever studied.
More comparisons
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Reviewed by Fat Man in the Arena · Updated March 2026
Medical Disclaimer: This comparison is for informational purposes only. Individual responses vary. Always consult a qualified healthcare provider before starting any peptide protocol.